Summary
The ascites of a 78-yr-old Japanese woman with cholangiocarcinoma was used for a primary culture. An established new cell line (designated TK from the Japanese description of cholangiocarcinoma; Tankan-gann) showed conspicuous tumor marker production. A high level of circulating serum tumor markers; carbohydrate antigen (CA) 19-9, 32,000 U/ml; CA50, 6900 U/ml; and carcinoembryonic antigen (CEA), 300 ng/ml (on an average from 106 cells/ml for 3 d culture) were detected in the tissue culture supernatant. With an inoculum of 2×107 TK cells, nude mice progressively developed tumors. The histological features of the tumors forming in nude mice showed well-differentiated adenocarcinoma. Within the tumor mass, large amounts of extra cellular fluid retained approximately 590,000 U/ml of CA19-9, 200,000 U/ml of CA50, and 2000 ng/ml of CEA. Alpha-feto-protein was undetectable in the TK culture supernatant. There are few cholangiocarcinoma cell lines producing stable human tumor markers. Newly established TK cells derived from cholangiocarcinoma showed a stable production of serum tumor markers in vivo and in vitro. The changes in the tumor marker secretion ratios were shown to be dependent upon type of tumor cells, i.e., whether they are in vitro or in vivo. These features make TK cells a valuable tool for studying tumor markers.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abelev, G. I. Alpha-fetoprotein as a marker of embryo-specific differentiation normal on human tissue. Transpl. Rev. 20:3–37; 1974.
Cascinu, S.; Del Ferro, E.; Barbanti, I.; Ligi, M.; Fedeli, A.; Catalano, G. Tumor markers in the diagnosis of malignant serous effusions. Am. J. Clin. Oncol. 20:247–250; 1997.
Del Villano, B. C.; Brennan, S.; Brock, P., et al. Radioimmunometric assay for a monoclonal antibody—defined tumor marker, CA 19-9. Clin. Chem. 29:549–552; 1983.
Gold, P.; Freedman, O. Demonstration of tumor specific antigen in human colonic carcinoma by immunologic tolerance and absorption techniques. J. Exp. Med. 127:439–462; 1965.
Hagland, C.; Lindgren, J.; Roberts, P. J.; Nordling, S. Difference in tissue expression on tumor markers CA19-9 and CA50 in hepatocellular carcinoma and cholangiocarcinoma. Br. J. Cancer 63:386–389; 1991.
Holmgren, J.; Lindholm, L.; Persson, B., et al. Detection by monoclonal antibody of carbohydrate antigen CA50 in serum of patients with carcinoma. Br. Med. J. 288:1479–1482; 1984.
Koh, K. K.; In, H. H.; Kim, E. J., et al. New scoring system using tumor markers in diagnosing patients with moderate pericardial effusions. Int. J. Cardiol. 61:5–13; 1997.
Koprowski, H.; Steplewski, Z.; Mitchell, K.; Herlyn, M.; Herlyn, D.; Furrer, P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet. 5:957–971; 1979.
Miyagiwa, M.; Ichida, T.; Tokiwa, T.; Sato, J.; Sasaki, H. A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium. In Vitro 25:503–510; 1989.
Nakamura, S.; Suzuki, S.; Sakaguchi, T.; Seerizawa, A.; Konno, H.; Baba, S.; Baba, S.; Muro, H. Surgical treatment of patients with mixed hepatocellular carcinoma and cholangiocarcinoma. Cancer 78:1671–1676; 1996.
Okuda, K.; Ohta, M.; Tsuchiya, Y. The role of ultrasound, percutaneous transhepatic cholangiography, computed tomographic scanning, and magnetic resonance imaging in the preoperative assessment of bile duct cancer. World J. Surg. 12:18–26; 1988.
Okuda, K.; Tsuchiya, Y.; Ohta, M. Ultrasound-guided transhepatic pancture in the diagnosis and management of hepatobiliary disorders. In: Popper H.; Schffner, F., ed. Progress in liver diseases. Vol. 8. New York: Grune & Stratton; 1986:643–658.
Pitt, H. A.; Dooley, W. C.; Yeo, C. J.; Cameron, J. L. Malignancies of the biliary tree. Curr. Probl. Surg. 32:1; 1995.
Pitt, H. A.; Grochow, L. B.; Abrams, R. A. Cancer of the biliary tree. In: Devita, V. T. Jr.; Hellman, S.; Rosenberg, S. A., ed. Cancer: principles and practice of oncology. Philadelphia, PA: Lippincott-Raven Publishers; 1997:1114–1128.
Ramage, J. K.; Donaghy, A.; Farrant, J. M.; Iorns, R.; Williams, R. Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangiotis. Gastroenterology 108:865–869; 1995.
Shimizu, Y.; Demetris, A.; Gollin, S. M., et al. Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int. J. Cancer 52:252–260; 1992.
Yamaguchi, K.; Enjoji, M.; Nakayama, F. Cancer of the extrahepatic bile duct: a clinicopathologic study of immuno-histochemistry for CEA, CA19-9, and p21. World J. Surg. 12:11–17; 1988.
Yamaguchi, N.; Morioka, H.; Ohkura, H.; Hirohashi, S.; Kawai, K. Establishment and characterization of the human cholangiocarcinoma cell line Hchol-1 in a serum-free, chemically defined medium. J. Natl. Cancer Inst. 75:29–35; 1985.
Yano, H.; Ieuma, A.; Haramaki, M.; Momosaki, S.; Ogasawara, S.; Higaki, K.; Kojiro, M. A human combined hepatocellular and cholangio-carcinoma cell line (KMCH-2) that shows the features of hepatocellular carcinoma or cholangiocarcinoma under different conditions. J. Hepatol. 24:413–422; 1996.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Watanabe, M., Chigusa, M., Takahashi, H. et al. High level of CA19-9, CA50, and CEA-producible human cholangiocarcinoma cell line changes in the secretion ratios in vitro or in vivo. In Vitro Cell.Dev.Biol.-Animal 36, 104–109 (2000). https://doi.org/10.1290/1071-2690(2000)036<0104:HLOCCA>2.0.CO;2
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1290/1071-2690(2000)036<0104:HLOCCA>2.0.CO;2